Introduction: Cost of Quality MCQs With Answer serves as a focused revision resource for M.Pharm students studying Quality Management Systems (MQA 102T). This compilation clarifies the concept of Cost of Quality (COQ) — covering prevention, appraisal, internal failure, and external failure costs — and links theory to practical pharmaceutical quality decisions. Questions are designed to probe both conceptual understanding and application: how COQ influences process improvement, regulatory compliance, and product lifecycle economics. Through scenario-based and calculation items, students will strengthen skills in identifying quality-related costs, prioritising preventive action, and interpreting COQ metrics for better decision-making in pharmaceutical manufacturing and quality assurance.
Q1. What is the primary objective of measuring Cost of Quality (COQ) in a pharmaceutical company?
- To increase sales revenue by lowering prices
- To quantify costs associated with achieving and not achieving quality and guide improvements
- To reduce employee salaries to cut expenses
- To measure the amount spent on marketing defective products
Correct Answer: To quantify costs associated with achieving and not achieving quality and guide improvements
Q2. Which of the following is NOT one of the traditional four categories of Cost of Quality?
- Prevention costs
- Appraisal costs
- Regulatory penalty costs
- Internal failure costs
Correct Answer: Regulatory penalty costs
Q3. Which cost category includes expenses for quality audits, validation of analytical methods, and incoming raw material testing?
- Prevention costs
- Appraisal costs
- External failure costs
- Internal failure costs
Correct Answer: Appraisal costs
Q4. Which of the following is a typical example of a prevention cost in pharmaceutical manufacturing?
- Rework of a failed batch
- Customer product recalls
- Training staff on Good Manufacturing Practices (GMP)
- Complaint handling and replacement shipments
Correct Answer: Training staff on Good Manufacturing Practices (GMP)
Q5. Internal failure costs in a drug product plant would most likely include:
- Costs of clinical trials
- Costs associated with scrap and reprocessing within the facility
- Costs for customer warranty claims
- Costs of preventive maintenance
Correct Answer: Costs associated with scrap and reprocessing within the facility
Q6. External failure costs are best described as:
- Costs from inspection and testing activities
- Expenses to prevent defects through training
- Costs incurred after the product reaches the customer due to defects
- Fixed overhead costs of the manufacturing facility
Correct Answer: Costs incurred after the product reaches the customer due to defects
Q7. Which statement correctly compares prevention and appraisal costs?
- Prevention costs are usually higher than appraisal costs and do not reduce failures
- Investing in prevention often reduces appraisal and failure costs over time
- Appraisal costs always eliminate the need for prevention costs
- Both categories are unrelated to product quality
Correct Answer: Investing in prevention often reduces appraisal and failure costs over time
Q8. The Cost of Poor Quality (COPQ) typically includes which combination?
- Only prevention and appraisal costs
- Only capital expenditures for plants
- Internal failure and external failure costs
- Marketing and distribution costs unrelated to quality
Correct Answer: Internal failure and external failure costs
Q9. Which metric would best show the economic benefit of quality improvement projects?
- Total number of employees trained
- Return on Quality (ROQ) or reduction in COPQ as percentage of sales
- Gross income before quality costs
- Amount spent on raw materials
Correct Answer: Return on Quality (ROQ) or reduction in COPQ as percentage of sales
Q10. A pharmaceutical plant reports the following annual figures: Prevention costs = $120,000; Appraisal costs = $80,000; Internal failure costs = $50,000; External failure costs = $150,000. What is the total Cost of Quality?
- $200,000
- $400,000
- $500,000
- $100,000
Correct Answer: $400,000
Q11. Using the same data (Prevention $120,000; Appraisal $80,000; Internal failure $50,000; External failure $150,000) and annual sales of $5,000,000, what is COQ as a percentage of sales?
- 8%
- 4%
- 10%
- 2%
Correct Answer: 8%
Q12. Which of the following best describes hidden costs of poor quality in a pharmaceutical setting?
- Costs that are recorded directly in the ledger as quality expenses
- Intangible or indirect costs such as lost market share, tarnished reputation, and regulatory delays
- The market price of raw materials
- Planned maintenance expenditures
Correct Answer: Intangible or indirect costs such as lost market share, tarnished reputation, and regulatory delays
Q13. Which tool is most useful to identify the few causes that contribute the majority of COQ and prioritize corrective actions?
- Histogram
- Pareto analysis
- Scatter diagram
- Control chart
Correct Answer: Pareto analysis
Q14. In COQ analysis, Taguchi’s loss function is primarily used to:
- Assign direct accounting values to inspection labor costs
- Quantify the societal and economic loss from deviation of product characteristics from the target
- Calculate depreciation on manufacturing equipment
- Estimate the cost of packaging materials
Correct Answer: Quantify the societal and economic loss from deviation of product characteristics from the target
Q15. Which action would most directly reduce external failure costs for a pharmaceutical firm?
- Increasing raw material purchase orders
- Implementing more rigorous process validation and batch release controls
- Cutting spending on preventive maintenance
- Reducing staff training hours
Correct Answer: Implementing more rigorous process validation and batch release controls
Q16. A quality manager claims that inspection is not a substitute for process control. Which reason supports this claim in terms of COQ?
- Inspection eliminates all customer complaints
- Inspection detects defects after they occur, increasing appraisal costs but not preventing failure costs
- Inspection is always cheaper than prevention
- Inspection increases external failure costs directly
Correct Answer: Inspection detects defects after they occur, increasing appraisal costs but not preventing failure costs
Q17. When analyzing COQ, which perspective is most important for long-term reduction of total quality costs?
- Focusing solely on minimizing appraisal costs
- Emphasising prevention to build quality into the process
- Eliminating all documentation to reduce paperwork costs
- Outsourcing all testing regardless of supplier capability
Correct Answer: Emphasising prevention to build quality into the process
Q18. Which of the following best describes the relationship between process capability (Cp, Cpk) and COQ?
- Higher process capability generally reduces failure costs and hence COQ
- Process capability only affects appraisal costs and not failures
- Lower process capability reduces scrap and rework costs
- Process capability metrics are unrelated to quality costs
Correct Answer: Higher process capability generally reduces failure costs and hence COQ
Q19. In a scenario where prevention spending is increased by $50,000 and annual failure costs drop by $200,000, what is the net immediate financial impact on COQ?
- COQ increases by $150,000
- COQ decreases by $150,000
- COQ remains unchanged
- COQ increases by $250,000
Correct Answer: COQ decreases by $150,000
Q20. For regulatory readiness, which COQ-related investment should be prioritized to avoid large external failure costs such as recalls and warning letters?
- Investment in cosmetic packaging redesign
- Investment in robust stability programs, batch traceability and CAPA systems
- Investment in sales promotions
- Investment in shifting production to unqualified suppliers
Correct Answer: Investment in robust stability programs, batch traceability and CAPA systems

I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com

